TIVOZANIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H19ClN4O5
Molecular Weight	454.863
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(C=C1OC)C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=N2

InChI

InChIKey=SPMVMDHWKHCIDT-UHFFFAOYSA-N

InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24019545
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23788831

Tivozanib (formerly AV-951, KRN-951) is a potent and selective VEGFR tyrosine kinase inhibitor and inhibits angiogenesis and vascular permeability in tumor tissues. It completed phase III a trial investigation for the treatment of renal cell carcinomas, but has not been still approved. In addition, this drug is in the phase II of clinical trial for the investigation it in patients with glioblastoma and colorectal carcinoma.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vascular endothelial growth factor receptor 11 Target ID: CHEMBL2095227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=16982756	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Renal cell carcinoma 33 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24019545	Primary	Phase III 665	Unknown Approved Use Unknown
Glioblastoma 66 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27853960	Primary	Phase II 1147	Unknown Approved Use Unknown
Colorectal cancer 102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27401244	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
12.1 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14.4 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
18.8 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.9 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
16.21 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.66 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.33 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.293 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	0.89 mg 1 times / day multiple, oral dose: 0.89 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.19 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day multiple, oral dose: 1.34 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.65 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.78 mg 1 times / day multiple, oral dose: 1.78 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
50.03 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	0.89 mg 1 times / day multiple, oral dose: 0.89 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
67.46 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day multiple, oral dose: 1.34 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
110 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.78 mg 1 times / day multiple, oral dose: 1.78 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.51 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day multiple, oral dose: 1.34 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
94.29 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day steady-state, oral dose: 1.34 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1084 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2491 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2309 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1680 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1960 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4449 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6715 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
131.2 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	0.89 mg 1 times / day multiple, oral dose: 0.89 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
159.2 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day multiple, oral dose: 1.34 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
274.3 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.78 mg 1 times / day multiple, oral dose: 1.78 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
856 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	0.89 mg 1 times / day multiple, oral dose: 0.89 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1180.2 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day multiple, oral dose: 1.34 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1997.2 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.78 mg 1 times / day multiple, oral dose: 1.78 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
258.2 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day multiple, oral dose: 1.34 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1640.6 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=266	1.34 mg 1 times / day steady-state, oral dose: 1.34 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
89.3 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
122 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
121 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
103 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
118.7 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
316.2 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
577.8 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=265	1.34 mg single, oral dose: 1.34 mg route of administration: Oral experiment type: SINGLE co-administered:	TIVOZANIB serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212904Orig1s000MultidisciplineR.pdf#page=177 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212904s000lbl.pdf#page=15			TIVOZANIB plasma	Homo sapiens

Doses

Dose	Population	Adverse events
2 mg 1 times / day multiple, oral Highest studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	DLT: Hypertension, Proteinuria... Dose limiting toxicities: Hypertension (grade 3, 28.6%) Proteinuria (grade 3, 14.3%) Ataxia (grade 3, 14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/
1.5 mg 1 times / day multiple, oral MTD Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	DLT: Hypertension, Serum transaminase increased... Dose limiting toxicities: Hypertension (12.5%) Serum transaminase increased (grade 3-4, 12.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/

AEs

AE	Significance	Dose	Population
Ataxia	grade 3, 14.3% DLT	2 mg 1 times / day multiple, oral Highest studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/
Proteinuria	grade 3, 14.3% DLT	2 mg 1 times / day multiple, oral Highest studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/
Hypertension	grade 3, 28.6% DLT	2 mg 1 times / day multiple, oral Highest studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/
Hypertension	12.5% DLT	1.5 mg 1 times / day multiple, oral MTD Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/
Serum transaminase increased	grade 3-4, 12.5% DLT	1.5 mg 1 times / day multiple, oral MTD Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/21976547/

PubMed

Title	Date	PubMed
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.	2013-04-15	23398362
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.	2012-12-27	23098265
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.	2011-10-30	22037377
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.	2008-03	18201272
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.	2006-09-15	16982756

Patents

Sample Use Guides

In Vivo Use Guide

Advanced Renal Cell Carcinoma: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.

Route of Administration: Oral

In Vitro Use Guide

KRN951 (TIVOZANIB) potently inhibited VEGF-induced VEGFR-2 phosphorylation in endothelial cells at in vitro subnanomolar IC50 values (IC50 = 0.16 nmol/L). It also inhibited ligand-induced phosphorylation of platelet-derived growth factor receptor-beta (PDGFR-beta) and c-Kit (IC50 = 1.72 and 1.63 nmol/L, respectively). KRN951 blocked VEGF-dependent, but not VEGF-independent, activation of mitogen-activated protein kinases and proliferation of endothelial cells. In addition, it inhibited VEGF-mediated migration of human umbilical vein endothelial cells.

Name

Type

Language

KIL-8951

Preferred Name

English

TIVOZANIB

Official Name

English

KIL8951

Code

English

UREA, N-(2-CHLORO-4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(5-METHYL-3-ISOXAZOLYL)-

Systematic Name

English

N-(2-CHLORO-4-((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-N'-(5-METHYLISOXAZOL-3-YL)UREA

Systematic Name

English

Tivozanib [WHO-DD]

Common Name

English

tivozanib [INN]

Common Name

English

KRN-951

Code

English

TIVOZANIB [USAN]

Common Name

English

AV-951

Code

English

Classification Tree Code System Code

WHO-ATC

L01XE34